Tristan R. Brown
Alternative energy, long/short equity, commodities, energy

Codexis Continues To Struggle With Little Relief In Sight

Executive Summary:

Codexis is a producer of cellulase and other enzymes used for the production of biofuels, detergent alcohols, and pharmaceutical ingredients. It's share price has fallen by 86% since its 2010 IPO and recently set a new low. The end of a R&D agreement with Shell, the possible end to an important licensing agreement with Dyadic, and faltering cellulosic ethanol production in the U.S. all raise serious concerns regarding the company's future growth prospects that investors should not overlook.

When I first began working in the biofuels sector back in 2008, a small company called Codexis (NASDAQ:CDXS) was attracting quite a bit of attention. The company was (and still is) a leading developer of a genetically-engineered enzyme...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details